
CHRS Valuation
Coherus Oncology Inc
- Overview
- Forecast
- Valuation
- Earnings
CHRS Relative Valuation
CHRS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CHRS is overvalued; if below, it's undervalued.
Historical Valuation
Coherus Oncology Inc (CHRS) is now in the Fair zone, suggesting that its current forward PS ratio of 2.39 is considered Fairly compared with the five-year average of -6.80. The fair price of Coherus Oncology Inc (CHRS) is between 0.80 to 2.10 according to relative valuation methord.
Relative Value
Fair Zone
0.80-2.10
Current Price:1.59
Fair
-1.47
PE
1Y
3Y
5Y
Trailing
Forward
0.12
EV/EBITDA
Coherus Oncology Inc. (CHRS) has a current EV/EBITDA of 0.12. The 5-year average EV/EBITDA is -14.71. The thresholds are as follows: Strongly Undervalued below -140.47, Undervalued between -140.47 and -77.59, Fairly Valued between 48.16 and -77.59, Overvalued between 48.16 and 111.04, and Strongly Overvalued above 111.04. The current Forward EV/EBITDA of 0.12 falls within the Historic Trend Line -Fairly Valued range.
0.07
EV/EBIT
Coherus Oncology Inc. (CHRS) has a current EV/EBIT of 0.07. The 5-year average EV/EBIT is -2.54. The thresholds are as follows: Strongly Undervalued below -43.25, Undervalued between -43.25 and -22.90, Fairly Valued between 17.82 and -22.90, Overvalued between 17.82 and 38.17, and Strongly Overvalued above 38.17. The current Forward EV/EBIT of 0.07 falls within the Historic Trend Line -Fairly Valued range.
2.39
PS
Coherus Oncology Inc. (CHRS) has a current PS of 2.39. The 5-year average PS is 2.07. The thresholds are as follows: Strongly Undervalued below -0.36, Undervalued between -0.36 and 0.85, Fairly Valued between 3.28 and 0.85, Overvalued between 3.28 and 4.50, and Strongly Overvalued above 4.50. The current Forward PS of 2.39 falls within the Historic Trend Line -Fairly Valued range.
-3.74
P/OCF
Coherus Oncology Inc. (CHRS) has a current P/OCF of -3.74. The 5-year average P/OCF is 2.64. The thresholds are as follows: Strongly Undervalued below -48.13, Undervalued between -48.13 and -22.74, Fairly Valued between 28.03 and -22.74, Overvalued between 28.03 and 53.42, and Strongly Overvalued above 53.42. The current Forward P/OCF of -3.74 falls within the Historic Trend Line -Fairly Valued range.
-4.11
P/FCF
Coherus Oncology Inc. (CHRS) has a current P/FCF of -4.11. The 5-year average P/FCF is -10.61. The thresholds are as follows: Strongly Undervalued below -59.47, Undervalued between -59.47 and -35.04, Fairly Valued between 13.82 and -35.04, Overvalued between 13.82 and 38.24, and Strongly Overvalued above 38.24. The current Forward P/FCF of -4.11 falls within the Historic Trend Line -Fairly Valued range.
Coherus Oncology Inc (CHRS) has a current Price-to-Book (P/B) ratio of 1.56. Compared to its 3-year average P/B ratio of -2.44 , the current P/B ratio is approximately -164.09% higher. Relative to its 5-year average P/B ratio of 1.87, the current P/B ratio is about -16.45% higher. Coherus Oncology Inc (CHRS) has a Forward Free Cash Flow (FCF) yield of approximately -56.57%. Compared to its 3-year average FCF yield of -50.21%, the current FCF yield is approximately 12.67% lower. Relative to its 5-year average FCF yield of -29.47% , the current FCF yield is about 91.96% lower.
1.54
P/B
Median3y
-2.44
Median5y
1.87
-56.57
FCF Yield
Median3y
-50.21
Median5y
-29.47
Competitors Valuation Multiple
The average P/S ratio for CHRS's competitors is 0.66, providing a benchmark for relative valuation. Coherus Oncology Inc Corp (CHRS) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -0.41%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CHRS increased by 52.88% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 1.82 to 3.11.
The secondary factor is the Revenue Growth, contributed -0.41%to the performance.
Overall, the performance of CHRS in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch

TWIN
Twin Disc Inc
14.570
USD
+9.30%

CBNA
Chain Bridge Bancorp Inc
31.790
USD
-2.03%

STRS
Stratus Properties Inc
22.300
USD
+2.53%

PEBK
Peoples Bancorp of North Carolina Inc
31.660
USD
+1.47%

MPTI
M-Tron Industries Inc
53.940
USD
+2.70%

ARTV
Artiva Biotherapeutics Inc
2.700
USD
-6.25%

CHSN
Chanson International Holding
2.610
USD
-5.43%

DOUG
Douglas Elliman Inc
2.980
USD
+0.34%

ZNTL
Zentalis Pharmaceuticals Inc
1.520
USD
0.00%

TARA
Protara Therapeutics Inc
3.670
USD
+15.05%
FAQ

Is Coherus Oncology Inc (CHRS) currently overvalued or undervalued?
Coherus Oncology Inc (CHRS) is now in the Fair zone, suggesting that its current forward PS ratio of 2.39 is considered Fairly compared with the five-year average of -6.80. The fair price of Coherus Oncology Inc (CHRS) is between 0.80 to 2.10 according to relative valuation methord.

What is Coherus Oncology Inc (CHRS) fair value?

How does CHRS's valuation metrics compare to the industry average?

What is the current P/B ratio for Coherus Oncology Inc (CHRS) as of Sep 23 2025?

What is the current FCF Yield for Coherus Oncology Inc (CHRS) as of Sep 23 2025?

What is the current Forward P/E ratio for Coherus Oncology Inc (CHRS) as of Sep 23 2025?
